Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.2.0.727
Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)
6 Months Ended
Jun. 30, 2015
USD ($)
Segment
Dec. 31, 2014
USD ($)
Summary Of Significant Accounting Policies [Line Items]    
Number of Operating segment | Segment 1  
Milestones arrangement, categories description Pieris Pharmaceuticals, Inc. aggregates milestones into three categories (i) research milestones, (ii) development milestones and (iii) commercial milestones.  
Effective tax rate 0.00%  
Fair Value, Inputs, Level 1 [Member]    
Summary Of Significant Accounting Policies [Line Items]    
Cash and Cash Equivalents, Fair Value $ 78,403 $ 4,800,573